Emerging Infectious Diseases | News, Research, Treatment Studies

Emerging Diseases

Emerging Diseases

Featured Article

Latest News

FDA Approves First-In-Class Antibiotic to Treat Community-Acquired Bacterial Pneumonia

The FDA has approved Xenleta (lefamulin; Nabriva Therapeutics) for the treatment of adults with community-acquired bacterial pneumonia (CABP) caused by the following susceptible microorganisms: Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae, Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydophila pneumoniae.